4146-30-9

Basic information

• Product Name: Framycetin sulphate
• Synonyms: Framycetin Sulfate;NeomycinBsulfate;D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1?3)-O-.beta.-D-ribofuranosyl-(1?5)-O-2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1?4)-2-deoxy-, sulfate (1:3) (salt);NEOMYCIN SULPHATE B(FRAMYCETIN SULPHATE);Neomycin sulphate B;(2R,3S,4R,5R,6R)-5-Amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2R,3R,4S,5R)-4-[(2S,3S,4S,5R,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxy-cyclohexyl]oxy-oxane-3,4-diol sulphate;Framycetin sulphate;4-O-(2,6-Diamino-2,6-dideoxy-α-D-glucopyranosyl)-5-O-[3-O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxy-D-streptamine/sulfuric acid,(1:3)
• CAS NO: 4146-30-9
• Molecular Formula: C₂₃H₄₆N₆O₁₃*3H₂O₄S
• Molecular Weight: 712.72
• EINECS: 223-969-3
• Product Categories: Inhibitors
• Mol File: 4146-30-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 927.1 °C at 760 mmHg
• Flash Point: 514.5 °C
• Appearance: COA
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Freely soluble in water, very slightly soluble in alcohol, practically insoluble in acetone.
• Stability: Hygroscopic
• CAS DataBase Reference: Framycetin sulphate(CAS DataBase Reference)
• NIST Chemistry Reference: Framycetin sulphate(4146-30-9)
• EPA Substance Registry System: Framycetin sulphate(4146-30-9)

Safety Data

• Hazardous Substances Data: 4146-30-9(Hazardous Substances Data)

Usage

Chemical Properties

White or yellowish-white powder, hygroscopic.

Uses

Antibacterial

Therapeutic Function

Antibacterial

InChI:InChI=1/C23H46N6O13.H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;(H2,1,2,3,4)/t5-,6+,7-,8-,9-,10-,11+,12+,13-,14+,15-,16+,17-,18-,19-,20-,21-,22+,23+;/m1./s1

Downstream Products

• 3947-65-7 neomycin A 
• 1393446-89-3 C₂₅H₄₈N₆O₁₄ 
• 1448168-05-5 3-C-azido neomycin B 
• 1315508-26-9 C₃₅H₄₀F₁₈N₆O₁₉ 
• 1229777-26-7 C₃₁H₆₂N₆O₁₃ 
• 1229777-23-4 C₃₁H₆₂N₆O₁₃ 
• 1229777-21-2 C₃₁H₆₂N₆O₁₃ 
• 1229777-24-5 C₃₁H₆₂N₆O₁₃ 
• 1229777-18-7 C₃₁H₆₂N₆O₁₃ 
• 1229777-27-8 C₃₁H₆₂N₆O₁₃ 
• 58096-78-9 Hexa-N-(benzyloxycarbonyl)neomycin B 
• 620172-15-8 C₄₁H₆₀N₁₈O₁₉Si 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Method for apparatus for a defined serumfree medical solution useful for corneal preservation

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.